Ultrasound identifies RA patients in clinical remission who need more intensive treatment

June 12, 2015

Rome, Italy, 12 June 2015: Two new studies presented at the European League Against Rheumatism Annual Congress (EULAR 2015) have shown the importance of using ultrasound to identify those Rheumatoid Arthritis (RA) patients in clinical remission who would benefit from more intensive treatment.

Many patients deemed to be in clinical remission still have active joint disease without any obvious symptoms or physical signs, but with risk of further progression of joint damage. Using ultrasound to predict the risk of flare and exacerbation of symptoms will allow these patients to receive additional treatment, preventing further joint damage and subsequent disability. The two studies highlight: EULAR recommendations state that remission (absent disease activity) is the target of treatment in patients with RA, and with modern therapeutic strategies, this target can be achieved more frequently. However, around one half of RA patients in clinical remission experiences a disease flare within 24 months.

Ultrasound diagnosis of tenosynovitis a reliable predictor of flare and symptom exacerbation1

"Although the role of ultrasound-diagnosed synovitis is well-known in the literature, no data are available for tenosynovitis," said lead investigator Dr. Emanuela Bellis of the Ospedale Mauriziano, Italy. "We have shown, for the first time, that an ultrasound diagnosis of tenosynovitis provides additional valuable information to the established use of ultrasound-diagnosed subclinical synovitis; it should therefore be routinely included in the management of RA patients in clinical remission," Dr Bellis concluded.

The STARTER study, conducted by the Musculoskeletal Ultrasound Study Group of the Italian Society of Rheumatology, evaluated the association between ultrasound-diagnosed synovitis and ultrasound-diagnosed tenosynovitis with the occurrence of flare over a 6-month period in RA patients in clinical remission.

Results confirmed the value of ultrasound-diagnosed synovitis in predicting flare, defined according to the patients' DAS28 score. However, ultrasound-diagnosed tenosynovitis was more specifically associated with flare as defined by symptom exacerbation, and the need to increase treatment.

A total of 427 consecutive patients with RA and clinical remission underwent a full clinical evaluation and ultrasound examination (assessing synovitis and tenosynovitis) at the wrists, hand and finger joints, and extensor/flexor tendon sheets. A flare was defined by an increase either in the DAS28 score >1.2 (or >0.6 if DAS28 ?3.2 at baseline), an increase in treatment, or a change of >4 points in the flare questionnaire if FQ<4 at baseline.

Identification and treatment of subclinical active synovitis prevents joint damage progression2

"Although the latest recommendations for the treatment of RA focus on the achievement of clinical remission, we have demonstrated that patients with subclinical synovitis as demonstrated by positive power Doppler signals on an ultrasound, should be treated more intensively to reduce the risk of further joint destruction, even when the patient is currently symptom-free," said study investigator Dr. Tadashi Okano, Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Japan.

To evaluate the potential benefit of prescribing additional intensive treatment to RA patients in clinical remission, patients in the SCRUM study with ultrasound-diagnosed subclinical synovitis were randomised to receive either an increased dose of methotrexate (MTX) or to stay on their current MTX dose.

Of 134 patients in clinical remission, ultrasound-positive synovitis was found in 101 patients (75.4%) at baseline. After randomisation, 51 patients were assigned to the MTX increasing group and 50 patients to the MTX stable group.

Initial results from the SCRUM study showed that progression of joint damage was significantly suppressed in the MTX increasing group compared to the MTX stable group at week 24 (p=0.007) and week 52 (p=0.038).
Abstract Numbers: OP0217; OP0219


For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress
Press Office in Room 5B of Fiera Roma during EULAR 2015 or on:
Email: eularpressoffice@cohnwolfe.com
Onsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442
Twitter: @EULAR_Press
Youtube: Eular Pressoffice


The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.

With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 19 health professionals associations and 21 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care.

EULAR 2015 is set to be the biggest rheumatology event in Europe with around 14,000 scientists, physicians, allied health professionals and related audiences in attendance from more than 120 countries. Over the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers.

To find out more about the activities of EULAR, visit: http://www.eular.org

European League Against Rheumatism

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.